Lonza Group Ltd
LO3
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
19,299
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,242.50 | 47.50 | -0.51% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,795.76 | 691.15 | 2.75% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,794.22 | 184.05 | 0.43% |
| NZX 50 Index | 13,079.50 | 114.57 | -0.87% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,970.90 | 53.50 | -0.59% |
| SSE Composite Index | 3,848.63 | 22.87 | 0.60% |